- Advanced imaging data sharing, analytics and visualization
platform that helps radiologists detect, diagnose and follow-up on
treatment of diseases
- IntelliSpace Portal 8.0 offers a comprehensive advanced
visualization suite for multi-modality tumor tracking,
characterization and assessment
- Latest edition debuts a fast and quantified 3-D
rendering[1] and analysis of tumor imaging for
research into treatment response
AMSTERDAM, Nov. 29, 2015 /PRNewswire/ -- Strengthening
its leadership in connected healthcare informatics, Royal Philips
(NYSE: PHG, AEX: PHIA) today announced IntelliSpace Portal 8.0, the
latest edition of its advanced data sharing, analytics and
visualization platform that helps radiologists detect, diagnose and
follow-up on treatment of diseases. Introduced at the 2015
Radiological Society of North America Annual Meeting (RSNA) in
Chicago, IL, IntelliSpace Portal
8.0 helps address the changing demands in radiology that result
from an increasing prevalence of cancer and its economic toll. It
delivers new applications – like fast 3-D quantitative renderings
of tumors – in a fully integrated oncology suite to improve
diagnostic confidence and patient care.
Photo - http://photos.prnewswire.com/prnh/20151124/290767
Photo - http://photos.prnewswire.com/prnh/20151124/290768
The oncology suite complements the width and depth of
applications that IntelliSpace Portal already offers as a
comprehensive, advanced analysis platform. The portal helps
clinicians visualize, diagnose, measure disease states and
communicate across modalities, with one efficient, automated, and
guided workflow. The latest release now boasts more than 68
clinical applications for 7 modalities including CT, MR,
Ultrasound, Mammography and iXR.
"Radiology has a unique ability to influence and improve
outcomes. Today there is so much data available, but its full
potential is not often realized," said Jeroen Tas, CEO, Healthcare
Informatics Solutions and Services, Philips. "Advances in digital
health technology now allow us to integrate clinical data from
multiple modalities and sources and make that data meaningful and
quickly accessible to radiologists. Innovations like the new 3-D
rendering of tumors in IntelliSpace Portal 8.0 can change the
trajectory of a cancer patient's journey to support the best path
to treatment."
Semi-automatic 3-D tumor quantification
concept
A key but challenging clinical need for today's
radiologists is determining how tumors are reacting to new local
image guided treatment approaches, such as tumor ablation and
chemoembolization. Currently, this is done by evaluating 1-D or 2-D
MRI-images taken after the procedure, which give only limited
insight and no quantified information. With the growing interest in
finding new 3-D quantification options, IntelliSpace Portal 8.0 now
includes, as an option for qualified researchers, a quantitative
technology (qEASL), which can be used in conjunction with its
Multi-Modality Tumor Tracking (MMTT) application. With this
technology, researchers can make a specialized analysis of 3-D
imaging scans (e.g. CT and MRI) with the aim to enhance measurement
of living and dying tumor tissue by giving them a visual indication
of how cells respond to therapy. qEASL has been developed in close
collaboration with leading clinical scientists at Yale School of
Medicine and aims to improve the current standard for cancer
treatment follow-ups as defined by the European Association for the
Study of the Liver (EASL)[2], [3].
"Image-guided local tumor therapies are very difficult to
evaluate for effectiveness, and traditional methods lack
reproducibility and involve some level of guesswork," said
Jean-Francois (Jeff) Geschwind, M.D., Chairman, Department of
Radiology and Biomedical Imaging at Yale School of Medicine.
"Redefining and standardizing how we assess this kind of treatment
is revolutionary for radiology and the kind of care we can deliver
for patients."
New applications
IntelliSpace Portal 8.0 features
enhanced capabilities and enriched clinical decision support.
- With the increasing interest in pulmonary care, IntelliSpace
Portal 8.0 now includes the new CT Lung Nodule Assessment
(LNA) application designed for a more efficient and
longitudinal workflow, which features a unique risk assessment
tool[4] for clinical decision support.
- Through the Lung Nodule CAD[5],
radiologists also have access to the computer-aided detection
system for chest multi-slice CT exams.
- A complete pulmonary solution, IntelliSpace Portal 8.0 also
includes applications to aid clinicians in measuring and tracking
COPD, detecting pulmonary emboli, and performing calcium
scoring.
- Embedded in the entire cardiac workflow, the MR Cardiac
Quantitative Mapping enables fast quantification and analysis
workflow for T1, T2, and T2 generated maps to enhance the
diagnostic view in cardiomyopathies (disease of the heart
muscle).
- Enhanced capabilities in the Multi-Modality Viewer allow
for the review, editing and analysis of Philips iXR and general
radiology datasets. MR Smart Display Protocols
deliver the best fitting display protocols for each individual
patient based on the radiologist's preferred initial viewing
layouts.
- The advanced capabilities of IntelliSpace Portal 8.0 will also
assist in complying with Meaningful Use legislation in the U.S. by
empowering radiologists to update EMRs easily and share patient
information with various organizations such as public health
agencies and specialized registries. With enhanced reporting
features, radiologists can augment clinical reports with exportable
graphs and tables, which can be collated into a single patient
report and stored directly on the PACS or RIS.
IntelliSpace Portal 8.0 will be showcased at booth #6736
at the RSNA Annual Meeting, taking place Nov. 29 - Dec. 4, in Chicago, Ill. A special event highlighting the
MMTT qEASL concept will be held at the Navy Pier on Tuesday, Dec. 1 from 6-8:30 p.m. CT. The event will feature Philips
physician partners from Yale
University, Charité Berlin
and MD Anderson discussing volumetric measurements as a concept for
response assessment in cancer treatment.
Follow @PhilipsLiveFrom or visit www.philips.com/rsna for
more information on Philips' presence at #RSNA15.
For further information, please contact:
Kathy O'Reilly
Philips Group Communications
(o) 978-659-2638 (mobile) 978-221-8919
Kathy.oreilly@philips.com
Twitter: @kathyoreilly
Joost Maltha
Philips Healthcare Informatics Solutions and Services
Mobile: +31610558116
Joost.Maltha@philips.com
About Royal
Philips
Royal Philips
(NYSE: PHG, AEX: PHIA) is a diversified health and well-being
company, focused on improving people's lives through meaningful
innovation in the areas of Healthcare, Consumer Lifestyle and
Lighting. Headquartered in the
Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately
106,000 employees with sales and services in more than 100
countries. The company is a leader in cardiac care, acute care and
home healthcare, energy efficient lighting solutions and new
lighting applications, as well as male shaving and grooming and
oral healthcare. News from Philips is located at
www.philips.com/newscenter.
[1] For research use only
[2] Comparison of Existing Response Criteria in Patients
with Hepatocellular Carcinoma Treated with TACE using a 3D
Quantitative Approach, Radiology, 2015.
[3] Radiologic-pathologic analysis of contrast-enhanced
and diffusion-weighted MR imaging in patients with HCC after TACE:
diagnostic accuracy of 3D quantitative image analysis, Radiology,
2014.
[4] Risk Calculator functionality not available for sale
in the US
[5] CAD functionality not available for sale in the
US